Sermorelin

Main evidence: Small human studies. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This draft separates sermorelin's historical pediatric evidence from unverified adult wellness claims.

What the sources say

A GHRH-plus-arginine protocol has been studied as a diagnostic stimulation test for adult growth hormone deficiency. That is evidence for diagnostic assessment, not a therapeutic peptide stack or a body-composition benefit. (Human clinical trials; Chanson et al., "Comparative validation of the growth hormone-releasing hormone and arginine test for the diagnosis of adult growth hormone deficiency," J Clin Endocrinol Metab, 2010-05-19)
In an open-label multicentre study of previously untreated prepubertal children with growth hormone deficiency, mean height velocity rose from 4.1 cm per year at baseline to 8.0 at 6 months and 7.2 at 12 months. The study was limited by its open-label design and one-year follow-up, and it did not establish final adult height. (Small human studies; Thorner et al., "Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy," J Clin Endocrinol Metab; checked 2026-10-28, 2026-10-28)
The pediatric trial evaluated children with diagnosed growth hormone deficiency; it does not establish sermorelin benefits for adult anti-ageing, body composition, sleep, athletic performance, or general wellness. (Small human studies; Thorner et al., "Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy," J Clin Endocrinol Metab; checked 2026-10-28, 2026-10-28)
Historical U.S. GEREF products were indicated for growth hormone deficiency in children with growth failure or for diagnostic assessment of pituitary growth-hormone secretion. FDA records say their approvals were withdrawn in 2009, but not for reasons of safety or effectiveness; this does not mean a currently marketed product is approved. (Educator material (not peer reviewed); U.S. Food and Drug Administration, "Determination That GEREF (Sermorelin Acetate) Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness," Federal Register, 2013-03-04)
The pediatric open-label study reported no adverse changes in its general biochemical or hormonal measures over the study period, but that limited observation cannot establish long-term safety or safety in other populations. (Small human studies; Thorner et al., "Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy," J Clin Endocrinol Metab; checked 2026-10-28, 2026-10-28)
The clinical review describes transient flushing and injection-site discomfort among reported effects in early use; the accessible historical sources do not provide a current comprehensive product label for individualized risk assessment. (Educator material (not peer reviewed); Prakash and Goa, "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency"; checked 2026-10-28, 2026-10-28)
The historical FDA notice says GEREF was withdrawn from sale for reasons other than safety or effectiveness; that regulatory determination does not establish long-term safety of current compounded products or adult off-label use. (Educator material (not peer reviewed); U.S. Food and Drug Administration, "Determination That GEREF (Sermorelin Acetate) Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness," Federal Register, 2013-03-04)
No sermorelin-specific Australian ARTG listing was verified in the public search reviewed on 2026-10-28. The result is reported cautiously because the ARTG search is not a legal determination about every possible exemption or access pathway. (Educator material (not peer reviewed); Therapeutic Goods Administration, Australian Register of Therapeutic Goods (ARTG) search; checked 2026-10-28, 2026-10-28)
The October 2026 Poisons Standard is the current instrument reviewed, but this draft does not assign a sermorelin-specific Schedule because a substance-specific classification was not verified in the materials reviewed. (Educator material (not peer reviewed); Federal Register of Legislation, Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, 2026-09-30)
Historical U.S. FDA approval and withdrawal records do not establish Australian registration or lawful supply in Australia. (Educator material (not peer reviewed); U.S. Food and Drug Administration, "Determination That GEREF (Sermorelin Acetate) Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness," Federal Register, 2013-03-04)

Sources

Dosing, stacking and protocol details are not published here.